John Sampson

Summary

Affiliation: Duke University Medical Center
Country: USA

Publications

  1. ncbi request reprint Comparison of intratumoral bolus injection and convection-enhanced delivery of radiolabeled antitenascin monoclonal antibodies
    John H Sampson
    Department of Surgery Neurosurgery, Duke University Medical Center, Durham, North Carolina 27710, USA
    Neurosurg Focus 20:E14. 2006
  2. pmc EGFRvIII-specific chimeric antigen receptor T cells migrate to and kill tumor deposits infiltrating the brain parenchyma in an invasive xenograft model of glioblastoma
    Hongsheng Miao
    Duke Brain Tumor Immunotherapy Program, Division of Neurosurgery, Department of Surgery, Duke University Medical Center, Durham, North Carolina, United States of America
    PLoS ONE 9:e94281. 2014
  3. pmc Myeloablative temozolomide enhances CD8⁺ T-cell responses to vaccine and is required for efficacy against brain tumors in mice
    Luis A Sanchez-Perez
    Duke Brain Tumor Immunotherapy Program, Division of Neurosurgery, Department of Surgery, Duke University Medical Center, Durham, North Carolina, United States of America
    PLoS ONE 8:e59082. 2013
  4. pmc A novel method for volumetric MRI response assessment of enhancing brain tumors
    Charles W Kanaly
    Division of Neurosurgery, Department of Surgery, Duke University Medical Center, Durham, North Carolina, United States of America
    PLoS ONE 6:e16031. 2011
  5. pmc A pilot study of IL-2Rα blockade during lymphopenia depletes regulatory T-cells and correlates with enhanced immunity in patients with glioblastoma
    John H Sampson
    Division of Neurosurgery, Department of Surgery, Duke University Medical Center, Durham, North Carolina, United States of America
    PLoS ONE 7:e31046. 2012
  6. ncbi request reprint Microvascular decompression for glossopharyngeal neuralgia: long-term effectiveness and complication avoidance
    John H Sampson
    Division of Neurosurgery, Department of Surgery, Duke University Medical Center, Box 3807, Durham, NC 27710, USA
    Neurosurgery 54:884-9; discussion 889-90. 2004
  7. pmc Tumor-specific immunotherapy targeting the EGFRvIII mutation in patients with malignant glioma
    John H Sampson
    Division of Neurosurgery, Department of Surgery, Duke University Medical Center, Durham, NC 27710, USA
    Semin Immunol 20:267-75. 2008
  8. pmc Sustained radiographic and clinical response in patient with bifrontal recurrent glioblastoma multiforme with intracerebral infusion of the recombinant targeted toxin TP-38: case study
    John H Sampson
    Duke University Medical Center, Durham, NC 27710, USA
    Neuro Oncol 7:90-6. 2005
  9. pmc Intracerebral infusion of an EGFR-targeted toxin in recurrent malignant brain tumors
    John H Sampson
    Division of Neurosurgery, Department of Surgery, Box 3050, Room 220 Sands Building, Duke University Medical Center, Durham, NC 27710, USA
    Neuro Oncol 10:320-9. 2008
  10. ncbi request reprint Intracerebral infusate distribution by convection-enhanced delivery in humans with malignant gliomas: descriptive effects of target anatomy and catheter positioning
    John H Sampson
    Department of Surgery, Division of Neurosurgery, Duke University Medical Center, Durham, North Carolina 27710, USA
    Neurosurgery 60:ONS89-98; discussion ONS98-9. 2007

Detail Information

Publications91

  1. ncbi request reprint Comparison of intratumoral bolus injection and convection-enhanced delivery of radiolabeled antitenascin monoclonal antibodies
    John H Sampson
    Department of Surgery Neurosurgery, Duke University Medical Center, Durham, North Carolina 27710, USA
    Neurosurg Focus 20:E14. 2006
    ..The purpose of this study was to determine if CED would provide a larger volume of distribution (Vd) of a radiolabeled monoclonal antibody (mAb) than a bolus injection...
  2. pmc EGFRvIII-specific chimeric antigen receptor T cells migrate to and kill tumor deposits infiltrating the brain parenchyma in an invasive xenograft model of glioblastoma
    Hongsheng Miao
    Duke Brain Tumor Immunotherapy Program, Division of Neurosurgery, Department of Surgery, Duke University Medical Center, Durham, North Carolina, United States of America
    PLoS ONE 9:e94281. 2014
    ..Together, these data demonstrate that systemically administered T cells are capable of migrating to the invasive edges of GBM to mediate antitumor efficacy and tumor regression. ..
  3. pmc Myeloablative temozolomide enhances CD8⁺ T-cell responses to vaccine and is required for efficacy against brain tumors in mice
    Luis A Sanchez-Perez
    Duke Brain Tumor Immunotherapy Program, Division of Neurosurgery, Department of Surgery, Duke University Medical Center, Durham, North Carolina, United States of America
    PLoS ONE 8:e59082. 2013
    ..Overall, these results may be used to leverage the side-effects of a clinically-approved chemotherapy and should be considered in future study design of immune-based treatments for brain tumors...
  4. pmc A novel method for volumetric MRI response assessment of enhancing brain tumors
    Charles W Kanaly
    Division of Neurosurgery, Department of Surgery, Duke University Medical Center, Durham, North Carolina, United States of America
    PLoS ONE 6:e16031. 2011
    ..Our approach appears to overcome many of the challenges with response assessment of enhancing brain tumors and warrants further examination and validation...
  5. pmc A pilot study of IL-2Rα blockade during lymphopenia depletes regulatory T-cells and correlates with enhanced immunity in patients with glioblastoma
    John H Sampson
    Division of Neurosurgery, Department of Surgery, Duke University Medical Center, Durham, North Carolina, United States of America
    PLoS ONE 7:e31046. 2012
    ..However, therapeutic approaches are complicated by the inadvertent inhibition of IL-2Rα expressing anti-tumor effector T-cells...
  6. ncbi request reprint Microvascular decompression for glossopharyngeal neuralgia: long-term effectiveness and complication avoidance
    John H Sampson
    Division of Neurosurgery, Department of Surgery, Duke University Medical Center, Box 3807, Durham, NC 27710, USA
    Neurosurgery 54:884-9; discussion 889-90. 2004
    ....
  7. pmc Tumor-specific immunotherapy targeting the EGFRvIII mutation in patients with malignant glioma
    John H Sampson
    Division of Neurosurgery, Department of Surgery, Duke University Medical Center, Durham, NC 27710, USA
    Semin Immunol 20:267-75. 2008
    ..The recurrence of EGFRvIII-negative tumors in our patients, however, highlights the need for targeting a broader repertoire of tumor-specific antigens...
  8. pmc Sustained radiographic and clinical response in patient with bifrontal recurrent glioblastoma multiforme with intracerebral infusion of the recombinant targeted toxin TP-38: case study
    John H Sampson
    Duke University Medical Center, Durham, NC 27710, USA
    Neuro Oncol 7:90-6. 2005
    ..This report describes a dramatic and sustained clinical and radiographic response in a patient with a bifrontal glioblastoma multiforme treated with intratumoral infusion of a novel targeted toxin, TP-38...
  9. pmc Intracerebral infusion of an EGFR-targeted toxin in recurrent malignant brain tumors
    John H Sampson
    Division of Neurosurgery, Department of Surgery, Box 3050, Room 220 Sands Building, Duke University Medical Center, Durham, NC 27710, USA
    Neuro Oncol 10:320-9. 2008
    ..However, the potential efficacy of drugs delivered by this technique may be severely constrained by ineffective infusion in many patients...
  10. ncbi request reprint Intracerebral infusate distribution by convection-enhanced delivery in humans with malignant gliomas: descriptive effects of target anatomy and catheter positioning
    John H Sampson
    Department of Surgery, Division of Neurosurgery, Duke University Medical Center, Durham, North Carolina 27710, USA
    Neurosurgery 60:ONS89-98; discussion ONS98-9. 2007
    ..The primary objective of this study was to quantitatively describe the distribution of a high molecular weight agent by CED relative to target anatomy and catheter position in patients with malignant gliomas...
  11. pmc Unarmed, tumor-specific monoclonal antibody effectively treats brain tumors
    J H Sampson
    Department of Surgery Neurosurgery, Duke University Medical Center, Durham, NC 27710, USA
    Proc Natl Acad Sci U S A 97:7503-8. 2000
    ..These data indicate that an unarmed, tumor-specific mAb may be an effective immunotherapy against human tumors and potentially other pathologic processes in the "immunologically privileged" central nervous system...
  12. doi request reprint Poor drug distribution as a possible explanation for the results of the PRECISE trial
    John H Sampson
    Division of Neurosurgery, Department of Surgery, Duke University, Durham, North Carolina, USA
    J Neurosurg 113:301-9. 2010
    ..The purpose of the present work was to retrospectively analyze the expected drug distribution based on catheter positioning data available from the CED arm of the PRECISE trial...
  13. pmc Clinical utility of a patient-specific algorithm for simulating intracerebral drug infusions
    John H Sampson
    Department of Surgery, Division of Neurosurgery, Duke University Medical Center, Durham, NC 27710, USA
    Neuro Oncol 9:343-53. 2007
    ..6% of catheters. Routine use of this algorithm, and its further developments, should improve prospective selection of catheter trajectories, and thereby improve the efficacy of drugs delivered by this promising technique...
  14. doi request reprint Is cytomegalovirus a therapeutic target in glioblastoma?
    John H Sampson
    Duke University Medical Center, Durham, North Carolina 27710, USA
    Clin Cancer Res 17:4619-21. 2011
    ..Is the level of CMV infection within tumor cells sufficient to drive important oncogenic or immunosuppressive processes? Can CMV serve as a target for therapeutic intervention?..
  15. pmc Colocalization of gadolinium-diethylene triamine pentaacetic acid with high-molecular-weight molecules after intracerebral convection-enhanced delivery in humans
    John H Sampson
    Division of Neurosurgery, Department of Surgery, Duke University Medical Center, Durham, North Carolina 27710, USA
    Neurosurgery 69:668-76. 2011
    ..CED is currently limited by suboptimal methodologies for monitoring the delivery of therapeutic agents that would permit technical optimization and enhanced therapeutic efficacy...
  16. doi request reprint Addition of bevacizumab to standard radiation therapy and daily temozolomide is associated with minimal toxicity in newly diagnosed glioblastoma multiforme
    James J Vredenburgh
    Department of Medicine, Duke University Medical Center, Durham, NC 27710, USA
    Int J Radiat Oncol Biol Phys 82:58-66. 2012
    ..To determine the safety of the addition of bevacizumab to standard radiation therapy and daily temozolomide for newly diagnosed glioblastoma multiforme (GBM)...
  17. pmc Bevacizumab plus irinotecan in recurrent WHO grade 3 malignant gliomas
    Annick Desjardins
    Department of Surgery, Duke University Medical Center, Durham, North Carolina 27710, USA
    Clin Cancer Res 14:7068-73. 2008
    ..We did a phase II trial of bevacizumab, a monoclonal antibody to vascular endothelial growth factor, in combination with irinotecan for patients with recurrent grade 3 malignant glioma...
  18. pmc Phase II study of metronomic chemotherapy with bevacizumab for recurrent glioblastoma after progression on bevacizumab therapy
    David A Reardon
    Department of Surgery, The Preston Robert Tisch Brain Tumor Center, Duke University Medical Center, Box 3624, Durham, NC 27710, USA
    J Neurooncol 103:371-9. 2011
    ..Alternative treatment strategies remain critically needed for this indication...
  19. pmc Phase II trial of temozolomide (TMZ) plus irinotecan (CPT-11) in adults with newly diagnosed glioblastoma multiforme before radiotherapy
    Jennifer A Quinn
    Department of Surgery, The Preston Robert Tisch Brain Tumor Center, Duke University Medical Center, Durham, NC 27710, USA
    J Neurooncol 95:393-400. 2009
    ..The lack of correlation of activity with MGMT expression is intriguing, but needs further evaluation in subsequent trials...
  20. pmc Clinical applications of a peptide-based vaccine for glioblastoma
    Charles W Kanaly
    Division of Neurosurgery, Department of Surgery, Duke University Medical Center, Box 3050, 220 Sands Building, Research Drive, Durham, NC 27710, USA
    Neurosurg Clin N Am 21:95-109. 2010
    ....
  21. ncbi request reprint Clinical immunotherapy for brain tumors
    Peter E Fecci
    Departments of Neurosurgery and Pathology, Duke University Medical Center, Durham, NC 27710, USA
    Neuroimaging Clin N Am 12:641-64. 2002
    ..Preclinical studies continue to play an important role in refining this form of active immunotherapy...
  22. pmc Phase 1 trial of temozolomide plus irinotecan plus O6-benzylguanine in adults with recurrent malignant glioma
    Jennifer A Quinn
    Department of Surgery, Duke University Medical Center, Durham, North Carolina, USA
    Cancer 115:2964-70. 2009
    ..The trial was designed to determine the maximum tolerated dose (MTD) and toxicity of irinotecan (CPT-11) when administered with temozolomide (TMZ) and O(6)-benzylguanine (O(6)-BG)...
  23. pmc Immunologic escape after prolonged progression-free survival with epidermal growth factor receptor variant III peptide vaccination in patients with newly diagnosed glioblastoma
    John H Sampson
    Duke University Medical Center, Durham, NC 27710, USA
    J Clin Oncol 28:4722-9. 2010
    ..Epidermal growth factor receptor variant III (EGFRvIII) is a constitutively activated and immunogenic mutation not expressed in normal tissues but widely expressed in glioblastoma multiforme (GBM) and other neoplasms...
  24. ncbi request reprint Induction of hyperintense signal on T2-weighted MR images correlates with infusion distribution from intracerebral convection-enhanced delivery of a tumor-targeted cytotoxin
    John H Sampson
    Department of Surgery, Duke University Medical Center, Durham, NC 27710, USA
    AJR Am J Roentgenol 188:703-9. 2007
    ..Our purpose was to test the hypothesis that hyperintense signal changes on T2-weighted images produced by such infusions can be used to track drug distribution...
  25. ncbi request reprint Bevacizumab plus irinotecan in recurrent glioblastoma multiforme
    James J Vredenburgh
    Preston Robert Tisch Brain Tumor Center, Duke University Medical Center, Durham, NC 27710, USA
    J Clin Oncol 25:4722-9. 2007
    ..We performed a phase II trial of bevacizumab, a monoclonal antibody to vascular endothelial growth factor, in combination with irinotecan...
  26. pmc Phase II trial of temozolomide plus o6-benzylguanine in adults with recurrent, temozolomide-resistant malignant glioma
    Jennifer A Quinn
    Departments of Surgery, Duke University Medical Center, PO Box 3624, Durham, NC 27710, USA
    J Clin Oncol 27:1262-7. 2009
    ....
  27. ncbi request reprint Immunotherapy of surgical malignancies
    Michael A Morse
    Duke University Medical Center, Durham, North Carolina, USA
    Curr Probl Surg 41:15-132. 2004
  28. pmc Molecular strategies for the treatment of malignant glioma--genes, viruses, and vaccines
    Lee A Selznick
    Division of Neurosurgery, Duke University Medical Center, Durham, NC, USA
    Neurosurg Rev 31:141-55; discussion 155. 2008
    ..This review will discuss the scientific background, therapeutic potential, and clinical limitations of these novel strategies with a focus on those that have made it to clinical trials...
  29. ncbi request reprint Profiling of CD4+, CD8+, and CD4+CD25+CD45RO+FoxP3+ T cells in patients with malignant glioma reveals differential expression of the immunologic transcriptome compared with T cells from healthy volunteers
    Chris A Learn
    Division of Neurosurgery, Department of Surgery, Duke University Medical Center, Durham, North Carolina 27710, USA
    Clin Cancer Res 12:7306-15. 2006
    ..Analyses of T-cell mRNA expression profiles in glioblastoma multiforme has not been previously reported but may help to define and characterize the immunosuppressed phenotype in patients with this type of cancer...
  30. ncbi request reprint Systemic anti-CD25 monoclonal antibody administration safely enhances immunity in murine glioma without eliminating regulatory T cells
    Peter E Fecci
    Department of Pathology, Duke University Medical Center, Durham, North Carolina 27710, USA
    Clin Cancer Res 12:4294-305. 2006
    ..We therefore examined T(regs) in mice bearing malignant glioma and evaluated anti-CD25 as an immunotherapeutic adjunct...
  31. pmc EGFRvIII-targeted immunotoxin induces antitumor immunity that is inhibited in the absence of CD4+ and CD8+ T cells
    Hidenobu Ochiai
    Department of Surgery Neurosurgery, Duke University Medical Center, Box 3050, Durham, NC, 27710, USA
    Cancer Immunol Immunother 57:115-21. 2008
    ..However, delayed and often dramatic antitumor responses seen in human studies with targeted toxins led us to hypothesize that immunologic responses may be a secondary mechanism that enhances the therapeutic efficacy of these novel drugs...
  32. ncbi request reprint Adoptive immunotherapy for malignant glioma
    Duane A Mitchell
    Department of Pathology and Department of Surgery, Duke University Medical Center, Box 3807, Durham, NC 27710, USA
    Cancer J 9:157-66. 2003
    ....
  33. ncbi request reprint Resistance to tyrosine kinase inhibition by mutant epidermal growth factor receptor variant III contributes to the neoplastic phenotype of glioblastoma multiforme
    Chris A Learn
    Department of Surgery, Division of Neurosurgery, Duke University Medical Center, Durham, North Carolina 27710, USA
    Clin Cancer Res 10:3216-24. 2004
    ..Determination of how this differential inhibition occurs may be important to patient selection and treatment criteria, as well as the design of future therapeutics for glioblastoma multiforme...
  34. ncbi request reprint Brain tumors in mice are susceptible to blockade of epidermal growth factor receptor (EGFR) with the oral, specific, EGFR-tyrosine kinase inhibitor ZD1839 (iressa)
    Amy B Heimberger
    Department of Surgery, Neurosurgery, Duke University Medical Center, Durham, North Carolina 27710, USA
    Clin Cancer Res 8:3496-502. 2002
    ..On the basis of these observations, we believe that clinical trials of ZD1839 against brain tumors expressing EGFR are warranted, but that special consideration should be given to tumors that coexpress EGFRvIII...
  35. pmc EGFRvIII-targeted vaccination therapy of malignant glioma
    Bryan D Choi
    Duke Brain Tumor Immunotherapy Program, Division of Neurosurgery, Department of Surgery, Duke University Medical Center, Durham, North Carolina 27710, USA
    Brain Pathol 19:713-23. 2009
    ..Additionally, the corresponding therapeutic outcomes observed in these studies lend credence to the potential role of peptide-based vaccination strategies among emerging antitumor immunotherapies in patients with malignant glioma...
  36. pmc Phase 2 trial of erlotinib plus sirolimus in adults with recurrent glioblastoma
    David A Reardon
    Department of Surgery, Duke University Medical Center, Durham, NC 27710, USA
    J Neurooncol 96:219-30. 2010
    ..029). Erlotinib plus sirolimus was well tolerated but had negligible activity among unselected recurrent GBM patients. (ClinicalTrials.gov number: NCT0062243)...
  37. ncbi request reprint Efficacy of intracerebral microinfusion of trastuzumab in an athymic rat model of intracerebral metastatic breast cancer
    Peter M Grossi
    Division of Neurosurgery, Department of Surgery, Duke University Medical Center, Durham, North Carolina 27710, USA
    Clin Cancer Res 9:5514-20. 2003
    ..Direct intracerebral microinfusion (ICM) is a technique that bypasses this blood-brain barrier and allows for a greater delivery of drugs directly into intracerebral tumors...
  38. pmc Toward effective immunotherapy for the treatment of malignant brain tumors
    Duane A Mitchell
    Duke Brain Tumor Immunotherapy Program, Division of Neurosurgery, Department of Surgery, Department of Pathology, Duke University Medical Center, Durham, North Carolina, USA
    Neurotherapeutics 6:527-38. 2009
    ....
  39. pmc Phase 2 trial of BCNU plus irinotecan in adults with malignant glioma
    David A Reardon
    Department of Surgery, Duke University Medical Center, Durham, NC 27710, USA
    Neuro Oncol 6:134-44. 2004
    ..9 weeks for recurrent anaplastic astrocytoma/ anaplastic oligodendroglioma patients. We conclude that the activity of BCNU plus CPT-11 for patients with MG appears comparable to that of CPT-11 alone and may be more toxic...
  40. pmc Phase I trial of temozolomide plus O6-benzylguanine 5-day regimen with recurrent malignant glioma
    Jennifer A Quinn
    Dept of Medicine, Division of Neurology, Duke University Medical Center, Durham, NC, USA
    Neuro Oncol 11:556-61. 2009
    ..This study provides the foundation for a phase II trial of O(6)-BG in combination with a 5-day dosing schedule of TMZ in TMZ-resistant MG...
  41. pmc Phase 1 trial of irinotecan plus BCNU in patients with progressive or recurrent malignant glioma
    Jennifer A Quinn
    Department of Surgery, Duke University Medical Center, Durham, NC 27710, USA
    Neuro Oncol 6:145-53. 2004
    ....
  42. pmc Phase II trial of Gliadel plus O6-benzylguanine in adults with recurrent glioblastoma multiforme
    Jennifer A Quinn
    Department of Surgery, Pathology, Biostatistics, and Bioinformatics, Duke University Medical Center, Durham, North Carolina 27710, USA
    Clin Cancer Res 15:1064-8. 2009
    ....
  43. pmc Proteomic and immunologic analyses of brain tumor exosomes
    Michael W Graner
    Department of Pathology, Duke University Medical Center, Durham, NC 27710, USA
    FASEB J 23:1541-57. 2009
    ..They can escape the blood-brain barrier, with potential systemic and distal signaling and immune consequences...
  44. pmc An epidermal growth factor receptor variant III-targeted vaccine is safe and immunogenic in patients with glioblastoma multiforme
    John H Sampson
    Division of Neurosurgery, Department of Surgery, Duke University Medical Center, Durham, North Carolina 27710, USA
    Mol Cancer Ther 8:2773-9. 2009
    ..7 months (C.I.(95), 14.5-25.6). Overall median survival from time of histologic diagnosis was 22.8 months (C.I.(95), 17.5-29). This study establishes the EGFRvIII mutation as a safe and immunogenic tumor-specific target for immunotherapy...
  45. pmc Convection-enhanced delivery of free gadolinium with the recombinant immunotoxin MR1-1
    Dale Ding
    School of Medicine, Duke University Medical Center, DUMC, Box 3050, 220 Sands Building, Research Drive, Durham, NC 27710, USA
    J Neurooncol 98:1-7. 2010
    ..Our data supports the use of Gd-DTPA, as a surrogate tracer, co-infused with MR1-1 for drug distribution monitoring in patients with GBM...
  46. ncbi request reprint Progress report of a Phase I study of the intracerebral microinfusion of a recombinant chimeric protein composed of transforming growth factor (TGF)-alpha and a mutated form of the Pseudomonas exotoxin termed PE-38 (TP-38) for the treatment of malignant b
    John H Sampson
    Division of Neurosurgery, Duke University Medical Center, Durham, NC 27710, USA
    J Neurooncol 65:27-35. 2003
    ..9 weeks. Overall, 3 of 15 patients, with residual disease at the time of therapy, have demonstrated radiographic responses and one patient with a complete response and has survived greater than 83 weeks...
  47. ncbi request reprint Dendritic cells pulsed with a tumor-specific peptide induce long-lasting immunity and are effective against murine intracerebral melanoma
    Amy B Heimberger
    Division of Neurosurgery, Department of Surgery, Duke University Medical Center, Durham, North Carolina 27710, USA
    Neurosurgery 50:158-64; discussion 164-6. 2002
    ..The purpose of this study was to demonstrate that DC-based immunizations directed solely against this tumor-specific antigen, which is commonly found on tumors that originate within or metastasize to the brain, could be efficacious...
  48. ncbi request reprint Generation of anti-idiotypic reagents in the EGFRvIII tumor-associated antigen system
    Carol J Wikstrand
    Department of Pathology, Box 3156, Medical Center, Duke University Medical Center, Durham, NC 27710, USA
    Cancer Immunol Immunother 50:639-52. 2002
    ....
  49. ncbi request reprint Phase II trial of murine (131)I-labeled antitenascin monoclonal antibody 81C6 administered into surgically created resection cavities of patients with newly diagnosed malignant gliomas
    David A Reardon
    Department of Surgery, Duke University Medical Center, Durham, NC 27710, USA
    J Clin Oncol 20:1389-97. 2002
    ..To assess the efficacy and toxicity of intraresection cavity (131)I-labeled murine antitenascin monoclonal antibody 81C6 and determine its true response rate among patients with newly diagnosed malignant glioma...
  50. ncbi request reprint Phase II trial of carmustine plus O(6)-benzylguanine for patients with nitrosourea-resistant recurrent or progressive malignant glioma
    Jennifer A Quinn
    Department of Surgery, Duke University Medical Center, Durham, NC 27710, USA
    J Clin Oncol 20:2277-83. 2002
    ....
  51. pmc Immunotherapy approaches for malignant glioma from 2007 to 2009
    Laura A Johnson
    Duke Brain Tumor Immunotherapy Program, Preston Robert Tisch Brain Tumor Center, Division of Neurosurgery, Department of Surgery, Duke University Medical Center, DUMC 3050, Sands Research Building, Durham, NC 27710, USA
    Curr Neurol Neurosci Rep 10:259-66. 2010
    ..We compare and discuss the current state of the art of clinical immunotherapy treatment, as well as its limited successes, pitfalls, and future potential...
  52. pmc Clinical trial end points for high-grade glioma: the evolving landscape
    David A Reardon
    The Preston Robert Tisch Brain Tumor Center at Duke, Duke University Medical Center, Box 3624, Durham, NC 27710, USA
    Neuro Oncol 13:353-61. 2011
    ..Technical advances in imaging as well as improved survival for patients with HGG support the further development of auxiliary end points evaluating novel imaging approaches as well as measures of patient function and well being...
  53. ncbi request reprint Phase II trial of temozolomide in patients with progressive low-grade glioma
    Jennifer A Quinn
    Department of Surgery, Duke University Medical Center, Durham, NC 27710, USA
    J Clin Oncol 21:646-51. 2003
    ..We have extended these results, and now we report results of a phase II trial of Temodar for patients with progressive, low-grade glioma...
  54. pmc Effect of CYP3A-inducing anti-epileptics on sorafenib exposure: results of a phase II study of sorafenib plus daily temozolomide in adults with recurrent glioblastoma
    David A Reardon
    Department of Surgery, Duke University Medical Center, Durham, NC, 27710, USA
    J Neurooncol 101:57-66. 2011
    ..In conclusion, sorafenib can be safely administered with daily temozolomide, but this regimen has limited activity for recurrent GBM. Co-administration of EIAEDs can lower sorafenib exposures in this population...
  55. ncbi request reprint Phase II trial of gefitinib in recurrent glioblastoma
    Jeremy N Rich
    Duke University Medical Center, Box 2900, Durham, NC 27710, USA
    J Clin Oncol 22:133-42. 2004
    ..To evaluate the efficacy and tolerability of gefitinib (ZD1839, Iressa; AstraZeneca, Wilmington, DE), a novel epidermal growth factor receptor tyrosine kinase inhibitor, in patients with recurrent glioblastoma...
  56. ncbi request reprint Detection of humoral response in patients with glioblastoma receiving EGFRvIII-KLH vaccines
    Robert J Schmittling
    Division of Neurosurgery, Department of Surgery, Duke University Medical Center, Durham, NC 27710, USA
    J Immunol Methods 339:74-81. 2008
    ..Using this assay, we found that significant levels of antibody for tumor-specific antigen EGFRvIII (>4 microg/mL) and KLH could be induced after vaccination with PEPvIII-KLH...
  57. ncbi request reprint Novel human IgG2b/murine chimeric antitenascin monoclonal antibody construct radiolabeled with 131I and administered into the surgically created resection cavity of patients with malignant glioma: phase I trial results
    David A Reardon
    Department of Surgery, The Preston Robert Tisch Brain Tumor Center, Duke University Medical Center, Durham, North Carolina, USA
    J Nucl Med 47:912-8. 2006
    ....
  58. ncbi request reprint Phase 1 trial of gefitinib plus sirolimus in adults with recurrent malignant glioma
    David A Reardon
    AstraZeneca Pharmaceuticals, Wilmington, Delaware, USA
    Clin Cancer Res 12:860-8. 2006
    ....
  59. ncbi request reprint Phase II study of imatinib mesylate plus hydroxyurea in adults with recurrent glioblastoma multiforme
    David A Reardon
    Department of Medicine, Cancer Institute, University of Pittsburgh, Pittsburgh, PA, USA
    J Clin Oncol 23:9359-68. 2005
    ....
  60. pmc Sensitive detection of human cytomegalovirus in tumors and peripheral blood of patients diagnosed with glioblastoma
    Duane A Mitchell
    Duke University Medical Center, Division of Neurosurgery, Department of Surgery, Durham, NC 27710, USA
    Neuro Oncol 10:10-8. 2008
    ....
  61. ncbi request reprint Phase I trial of temozolomide plus O6-benzylguanine for patients with recurrent or progressive malignant glioma
    Jennifer A Quinn
    Department of Surgery, Duke University Medical Center, Durham, NC, USA
    J Clin Oncol 23:7178-87. 2005
    ..In addition, plasma concentrations of O6-BG and O6-benzyl-8-oxoguanine were evaluated after O6-BG...
  62. pmc Immunotherapy of malignant brain tumors
    Duane A Mitchell
    Division of Neurosurgery, Department of Surgery, The Preston Robert Tisch Brain Tumor Center, Duke, NC 27710, USA
    Immunol Rev 222:70-100. 2008
    ....
  63. doi request reprint Cryptococcal meningitis in patients with glioma: a report of two cases
    Jonathan D Choi
    Division of Neurosurgery, Department of Surgery, Duke University School of Medicine, Durham, NC 27705, USA
    J Neurooncol 89:51-3. 2008
    ..This report of two cases highlights the importance of examining the efficacy of prophylactic antibiotic and/or antifungal regimens in this patient population due to their increased risk of opportunistic infections...
  64. ncbi request reprint Phase II study of imatinib mesylate and hydroxyurea for recurrent grade III malignant gliomas
    Annick Desjardins
    Department of Medicine, Division of Neurology, The Preston Robert Tisch Brain Tumor Center at Duke, Duke University Medical Center, Box 3624, Durham, NC 27710, USA
    J Neurooncol 83:53-60. 2007
    ..We performed the current phase 2 study to evaluate this regimen among patients with recurrent WHO grade III malignant glioma (MG)...
  65. pmc Selective modification of antigen-specific T cells by RNA electroporation
    Duane A Mitchell
    Division of Neurosurgery, Department of Surgery, Preston Robert Tisch Brain Tumor Center at Duke, Duke University Medical Center, Durham, NC 27710, USA
    Hum Gene Ther 19:511-21. 2008
    ....
  66. doi request reprint Immunotherapy against angiogenesis-associated targets: evidence and implications for the treatment of malignant glioma
    Richard G Everson
    Division of Neurosurgery, Department of Surgery, Box 3050 Med Ctr, Preston Robert Tisch Brain Tumor Center at Duke University, Durham, NC 27710, USA
    Expert Rev Anticancer Ther 8:717-32. 2008
    ....
  67. pmc Genetic analysis of intracranial tumors in a murine model of glioma demonstrate a shift in gene expression in response to host immunity
    Chris A Learn
    Division of Neurosurgery, Department of Surgery, Duke University Medical Center, Durham, NC 27710, United States
    J Neuroimmunol 182:63-72. 2007
    ..Our findings support our hypothesis that glioma phenotype in vitro may be quite different in vivo and significantly altered by in situ growth factors and other invading cell populations...
  68. ncbi request reprint Preoperative functional MR imaging localization of language and motor areas: effect on therapeutic decision making in patients with potentially resectable brain tumors
    Jeffrey R Petrella
    Department of Radiology, Division of Neuroradiology, Brain Imaging and Analysis Center, Duke University Medical Center, Box 3808, Durham, NC 27710 3808, USA
    Radiology 240:793-802. 2006
    ..To prospectively evaluate the effect of preoperative functional magnetic resonance (MR) imaging localization of language and motor areas on therapeutic decision making in patients with potentially resectable brain tumors...
  69. ncbi request reprint Mutant epidermal growth factor receptor up-regulates molecular effectors of tumor invasion
    Anita Lal
    Department of Pathology, Duke University Medical Center, Durham, North Carolina 27710, USA
    Cancer Res 62:3335-9. 2002
    ..Furthermore, inhibitors of EGFR (OSI-774 and Tyrphostin AG1478) selectively down-regulated these molecular effectors in glioblastoma cells, eliminating enhanced invasion...
  70. ncbi request reprint The history, evolution, and clinical use of dendritic cell-based immunization strategies in the therapy of brain tumors
    Peter E Fecci
    Department of Pathology, Duke University Medical Center, Durham, NC 27710, USA
    J Neurooncol 64:161-76. 2003
    ..The future success of clinical trials will depend on the optimization and standardizing of procedures for DC generation, loading, and administration...
  71. ncbi request reprint Systemic CTLA-4 blockade ameliorates glioma-induced changes to the CD4+ T cell compartment without affecting regulatory T-cell function
    Peter E Fecci
    Division of Neurosurgery, Department of Surgery, Duke University Medical Center, Durham, North Carolina 27710, USA
    Clin Cancer Res 13:2158-67. 2007
    ..Our murine glioma model recapitulates these findings. Here, we investigate the effects of systemic CTLA-4 blockade in this model...
  72. ncbi request reprint Bevacizumab fails to treat temporal paraganglioma: discussion and case illustration
    Hamidreza Aliabadi
    Department of Surgery, Division of Neurosurgery, Duke University Medical Center, 220 Sands Building, Research Drive, Box 3050, Durham, NC 27710, USA
    J Neurooncol 98:427-30. 2010
    ..This patient was treated with bevacizumab prior to surgical treatment; radiographic imaging at 3 months, however, showed no significant response. We discuss possible reasons for treatment failure...
  73. ncbi request reprint Increased regulatory T-cell fraction amidst a diminished CD4 compartment explains cellular immune defects in patients with malignant glioma
    Peter E Fecci
    Division of Neurosurgery, Department of Surgery, Duke University Medical Center, Durham, North Carolina 27710, USA
    Cancer Res 66:3294-302. 2006
    ..These findings dramatically alter our understanding of depressed cellular immune function in patients with malignant glioma and advance a role for T(regs) in facilitating tumor immune evasion in the central nervous system...
  74. ncbi request reprint Surgical management of petroclival meningiomas: defining resection goals based on risk of neurological morbidity and tumor recurrence rates in 137 patients
    Kenneth M Little
    Division of Neurosurgery, Duke University Medical Center, Durham, North Carolina 27710, USA
    Neurosurgery 56:546-59; discussion 546-59. 2005
    ..We sought to define optimal resection goals based on risk factors for postoperative neurological morbidity and tumor recurrence rates...
  75. pmc Melanoma immunotherapy using mature DCs expressing the constitutive proteasome
    Jens Dannull
    Department of Surgery, Duke University Medical Center, Durham, North Carolina, USA
    J Clin Invest 123:3135-45. 2013
    ..Since proteasomes generate peptides presented by HLA class I molecules, we hypothesized that mature melanoma antigen-loaded DCs engineered to process antigens through cPs would be superior inducers of antimelanoma immunity in vivo...
  76. ncbi request reprint Treatment of neoplastic meningitis with intrathecal 9-nitro-camptothecin
    Hidenobu Ochiai
    Division of Neurosurgery, Department of Surgery, Duke University Medical Center, Durham, North Carolina, USA
    Neurol Med Chir (Tokyo) 46:485-9; discussion 489-90. 2006
    ..005). These results suggest that intrathecal treatment with 9NC may be useful for patients with GBM neoplastic meningitis...
  77. ncbi request reprint Targeted therapy for glioblastoma multiforme neoplastic meningitis with intrathecal delivery of an oncolytic recombinant poliovirus
    Hidenobu Ochiai
    Division of Neurosurgery, Department of Surgery, Duke University Medical Center, Durham, North Carolina 27710, USA
    Clin Cancer Res 12:1349-54. 2006
    ..The toxicity and antitumor activity of regional intrathecal delivery of an oncolytic recombinant poliovirus, PVS-RIPO, was evaluated in rodent models of glioblastoma multiforme neoplastic meningitis...
  78. ncbi request reprint Safety of intraparenchymal convection-enhanced delivery of cintredekin besudotox in early-phase studies
    Sandeep Kunwar
    Department of Neurosurgery, University of California, San Francisco, California 94143 0350, USA
    Neurosurg Focus 20:E15. 2006
    ..Cintredekin besudotox (also known as IL13- PE38QQR) is a recombinant chimeric cytotoxin consisting of interleukin-13 and a truncated exotoxin produced by the Pseudomonas aeruginosa bacterium, which targets malignant glioma cells...
  79. ncbi request reprint Convection-enhanced delivery of therapeutics for brain disease, and its optimization
    Raghu Raghavan
    Therataxis, LLC, Baltimore, Maryland 21210 2415, USA
    Neurosurg Focus 20:E12. 2006
    ..In the present paper we review key features of CED as well as modeling of the procedure and indulge in informed speculation on optimizing the direct delivery of therapeutic agents into brain tissue...
  80. ncbi request reprint Convection-enhanced delivery of cintredekin besudotox (interleukin-13-PE38QQR) followed by radiation therapy with and without temozolomide in newly diagnosed malignant gliomas: phase 1 study of final safety results
    Michael A Vogelbaum
    Brain Tumor and Neuro Oncology Center, The Cleveland Clinic Foundation, Cleveland, Ohio 44195, USA
    Neurosurgery 61:1031-7; discussion 1037-8. 2007
    ....
  81. pmc Immunological responses in a patient with glioblastoma multiforme treated with sequential courses of temozolomide and immunotherapy: case study
    Amy B Heimberger
    Department of Neurosurgery, University of Texas M D Anderson Cancer Center, Houston, TX 77030 4009, USA
    Neuro Oncol 10:98-103. 2008
    ..In fact, the temozolomide-induced lymphopenia may prove to be synergistic with a peptide vaccine secondary to inhibition of regulatory T cells or their delayed recovery...
  82. ncbi request reprint Epidermal growth factor receptor VIII peptide vaccination is efficacious against established intracerebral tumors
    Amy B Heimberger
    Department of Neurosurgery, The University of Texas M D Anderson Cancer Center, Unit 442, 1515 Holcombe Boulevard, Houston, TX 77030, USA
    Clin Cancer Res 9:4247-54. 2003
    ..In the study described here, we tested in mouse models a vaccine consisting of a peptide encompassing the tumor-specific mutated segment of EGFRvIII (PEP-3) conjugated to keyhole limpet hemocyanin [KLH (PEP-3-KLH)]...
  83. ncbi request reprint Direct intracerebral delivery of cintredekin besudotox (IL13-PE38QQR) in recurrent malignant glioma: a report by the Cintredekin Besudotox Intraparenchymal Study Group
    Sandeep Kunwar
    Department of Neurological Surgery, University of California San Francisco, San Francisco, CA, 94143 0350, USA
    J Clin Oncol 25:837-44. 2007
    ..We assessed the use of intracerebral CED to deliver CB in patients with recurrent malignant glioma (MG)...
  84. ncbi request reprint Viruses in the treatment of malignant glioma
    Richard G Everson
    Expert Rev Neurother 7:321-4. 2007
  85. ncbi request reprint Viruses in the treatment of brain tumors
    Peter E Fecci
    Departments of Neurosurgery and Pathology, Duke University Medical Center, Durham, NC 27710, USA
    Neuroimaging Clin N Am 12:553-70. 2002
    ..Despite some promise afforded by these trials, further studies are warranted; the investigation of additional viruses to play these roles is inevitable and is now precedented...
  86. ncbi request reprint Treatment of intracerebral neoplasia and neoplastic meningitis with regional delivery of oncolytic recombinant poliovirus
    Hidenobu Ochiai
    Department of Surgery, Duke University Medical Center, Durham, North Carolina 27710, USA
    Clin Cancer Res 10:4831-8. 2004
    ..We have evaluated a novel therapeutic approach against CNS complications of breast cancer based on the human neuropathogen poliovirus (PV)...
  87. pmc A novel inhibitor of signal transducers and activators of transcription 3 activation is efficacious against established central nervous system melanoma and inhibits regulatory T cells
    Ling Yuan Kong
    Department of Neurosurgery, The University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
    Clin Cancer Res 14:5759-68. 2008
    ..We hypothesized that WP1066, a novel STAT3 blockade agent, has marked antitumor activity, even against the melanoma metastasis to brain, a site typically refractory to therapies...
  88. pmc Combating immunosuppression in glioma
    Eleanor A Vega
    Duke University School of Medicine, Department of Surgery, Division of Neurosurgery, 221 Sands Building, Durham, NC 27710, USA
    Future Oncol 4:433-42. 2008
    ..In addition, vaccination against Foxp3 has been explored. The results of these studies have been encouraging; combating immunosuppression may be one key to improving prognosis in malignant glioma...
  89. pmc Poliovirus receptor CD155-targeted oncolysis of glioma
    Melinda K Merrill
    Department of Molecular Genetics and Microbiology, Duke University Medical Center, Durham, NC 27710, USA
    Neuro Oncol 6:208-17. 2004
    ..Upregulation of the molecular target CD155 rendered explant cultures of all studied tumors highly susceptible to a prototype oncolytic poliovirus recombinant. Our observations support the clinical application of such agents against HGL...

Research Grants20

  1. Intracerebral Infusion of Radiolabeled Specific Antibody
    John Sampson; Fiscal Year: 2006
    ..abstract_text> ..
  2. MENTORED PATIENT ORIENTED RESEARCH CAREER DEVELOPMENT AW
    John Sampson; Fiscal Year: 2000
    ....
  3. RNA-based Immunotherapy Targeting Antigens Unique to Brain Tumor Stem Cells
    John Sampson; Fiscal Year: 2009
    ..PHS 398/2590 (Rev. 11/07) Page 1 Continuation Format Page ..
  4. RNA-based Immunotherapy Targeting Antigens Unique to Brain Tumor Stem Cells
    John Sampson; Fiscal Year: 2009
    ..In this proposal we will see if targeting antigens preferentially or uniquely expressed by BTSCs will enhance the efficacy and reduce toxicity of immunotherapy. ..
  5. Dendritic Cell Immunotherapy of Malignant Gliomas
    John Sampson; Fiscal Year: 2006
    ..abstract_text> ..
  6. RNA-based Immunotherapy Targeting Antigens Unique to Brain Tumor Stem Cells
    John H Sampson; Fiscal Year: 2010
    ..In this proposal we will see if targeting antigens preferentially or uniquely expressed by BTSCs will enhance the efficacy and reduce toxicity of immunotherapy. ..
  7. MENTORED PATIENT ORIENTED RESEARCH CAREER DEVELOPMENT AW
    John Sampson; Fiscal Year: 2004
    ....
  8. MENTORED PATIENT ORIENTED RESEARCH CAREER DEVELOPMENT AW
    John Sampson; Fiscal Year: 2003
    ....
  9. MENTORED PATIENT ORIENTED RESEARCH CAREER DEVELOPMENT AW
    John Sampson; Fiscal Year: 2001
    ....
  10. Intracerebral Infusion of Radiolabeled Specific Antibody
    John Sampson; Fiscal Year: 2002
    ..abstract_text> ..
  11. Dendritic Cell Immunotherapy of Malignant Gliomas
    John Sampson; Fiscal Year: 2002
    ..abstract_text> ..
  12. Intracerebral Infusion of Radiolabeled Specific Antibody
    John Sampson; Fiscal Year: 2003
    ..abstract_text> ..
  13. Dendritic Cell Immunotherapy of Malignant Gliomas
    John Sampson; Fiscal Year: 2004
    ..abstract_text> ..
  14. Intracerebral Infusion of Radiolabeled Specific Antibody
    John Sampson; Fiscal Year: 2005
    ..abstract_text> ..
  15. Dendritic Cell Immunotherapy of Malignant Gliomas
    John Sampson; Fiscal Year: 2003
    ..abstract_text> ..
  16. Dendritic Cell Immunotherapy of Malignant Gliomas
    John Sampson; Fiscal Year: 2005
    ..abstract_text> ..
  17. MENTORED PATIENT ORIENTED RESEARCH CAREER DEVELOPMENT AW
    John Sampson; Fiscal Year: 2002
    ....
  18. Intracerebral Infusion of Radiolabeled Specific Antibody
    John Sampson; Fiscal Year: 2004
    ..abstract_text> ..